The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
May 11th 2024
As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.
Karin Schenck-Gustafsson, MD, PhD, FESC: Why Sex and Gender Must be Considered in Disease Treatment
Karin Schenck-Gustafsson, MD, PhD, FESC, explains why sex and gender must be taken into account when treating and managing patients with rheumatic disease from a cardiologist's perspective.
Line Uhrenholt, MD: Disease Activity-Guided Tapering in Patients with Inflammatory Arthritis
Line Uhrenholt, MD, discusses the results of her randomized, open-label, equivalence trial study evaluating disease activity-guided tapering of biologics in patients with inflammatory arthritis.
Rheumatoid Arthritis Quiz: Bridging Therapy
June 6th 2022Glucocorticoids are sometimes used as “bridging” therapy to alleviate symptoms in newly diagnosed patients with rheumatoid arthritis (RA) prescribed a disease-modifying antirheumatic drug (DMARD), until the DMARD kicks in. Test your knowledge of bridging therapy with this quiz.
Patient-Provider Satisfaction Survey Affected by Cultural Norms in Hispanic/Latinx Patients with RA
A recent study, conducted by CreakyJoints, demonstrated that patient-reported satisfaction is affected by both social and cultural norms in Spanish-speaking patients with rheumatoid arthritis.
Filip Van den Bosch, MD: Safety and Efficacy of Upadacitinib for nr-axSpA
Filip Van den Bosch, MD, discusses his presentation, “Efficacy and Safety of Upadacitinib in Patients With Active Non-Radiographic Axial Spondyloarthritis: a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial."
Albert Roy: Clinically Significant Phase 2 Data Evaluates Deucravacitinib for SLE Treatment
Albert Roy, of Lupus Therapeutics, comments on the recent phase 2 trial data that evaluated deucravacitinib compared with placebo in patients with moderate-to-severe systemic lupus erythematosus.
Upadacitinib Achieves Promising Results for Axial Spondyloarthritis Treatment
June 3rd 2022Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.
John K Botson, MD, RPh, CCD: Pegloticase Combination Therapy for Uncontrolled Gout
John K. Botson MD, RPh, CCD, discusses results from the MIRROR trial, which evaluated the efficacy and safety of pegloticase injection in combination with methotrexate in patients with uncontrolled gout.
Improve Shared Decision Making Between Providers and Patients with Rheumatic Disease
June 1st 2022Research presented at EULAR aims to enhance communication with a conversation aid so patients can address challenges they encounter as a result of rheumatic and musculoskeletal disease with a rheumatologist.